The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2021 | CAR-T therapy vs. ASCT for myeloma
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses whether autologous stem cell transplant (ASCT) is still necessary with the recent successes of CAR-T therapy. In some countries (such as the US), there has been a recent reduction in the number of myeloma patients having ASCT. Prof. Nagler suggests that this is partly due to the rise of CAR-T, as well as novel agents. However, due to the high cost of CAR-T therapy many countries will continue to use ASCT for the foreseeable future. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
